These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34138519)

  • 1. STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
    Huvila J; Cochrane DR; Ta M; Chow C; Greening K; Leung S; Karnezis AN; DiFeo A; Huntsman DG
    J Pathol Clin Res; 2021 Nov; 7(6):548-555. PubMed ID: 34138519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases.
    Liang L; Jiang Y; Chen JS; Niu N; Piao J; Ning J; Zu Y; Zhang J; Liu J
    Hum Pathol; 2016 Nov; 57():1-6. PubMed ID: 27349304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.
    Altman AD; Nelson GS; Ghatage P; McIntyre JB; Capper D; Chu P; Nation JG; Karnezis AN; Han G; Kalloger SE; Köbel M
    Mod Pathol; 2013 Sep; 26(9):1255-63. PubMed ID: 23558569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The life and times of low-grade serous carcinoma of the ovary.
    Gershenson DM
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.
    Zheng W; Fadare O
    Int J Clin Exp Pathol; 2012; 5(3):182-6. PubMed ID: 22558471
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
    Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
    Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
    Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
    Morrison JC; Blanco LZ; Vang R; Ronnett BM
    Am J Surg Pathol; 2015 Apr; 39(4):442-53. PubMed ID: 25517955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
    Chen H; Molberg K; Strickland AL; Castrillon DH; Carrick K; Jiang Q; Niu S; Rivera-Colon G; Gwin K; Hinson S; Lea J; Miller DS; Zheng W; Lucas E
    Am J Surg Pathol; 2020 Aug; 44(8):1050-1060. PubMed ID: 32384321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
    Ramalingam P
    Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase.
    Sehdev AS; Kurman RJ; Kuhn E; Shih IeM
    Mod Pathol; 2010 Jun; 23(6):844-55. PubMed ID: 20228782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
    Ritterhouse LL; Nowak JA; Strickland KC; Garcia EP; Jia Y; Lindeman NI; Macconaill LE; Konstantinopoulos PA; Matulonis UA; Liu J; Berkowitz RS; Nucci MR; Crum CP; Sholl LM; Howitt BE
    Mod Pathol; 2016 Aug; 29(8):893-903. PubMed ID: 27150160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
    Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
    J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory role of prohibitin in human ovarian epithelial cancer.
    Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
    Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.